Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown133%
recruiting133%
withdrawn133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

NCT06811233
unknownearly_phase_1

The Individual Therapy for Patients With Wilson's Disease

NCT03957720
withdrawnphase_2

Mercury Chelation to Treat Autism

NCT00376194

Clinical Trials (3)

Showing 3 of 3 trials
NCT06811233Phase 2

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Recruiting
NCT03957720Early Phase 1

The Individual Therapy for Patients With Wilson's Disease

Unknown
NCT00376194Phase 2

Mercury Chelation to Treat Autism

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3